Itching to Know: Role of Fibrates in PBC

Levy, Cynthia; Lindor, Keith D.

doi:10.1038/ajg.2017.432

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pareset et al also used fibrate as an added therapy to UDCA in PBC patients and observed normalization of ALP in half of the study subjects. Furthermore, their research showed major improvement in pruritus [ 204 ]. The study by Wang et al analyzed UDCA-refractory PBC patients with a subgroup receiving combined therapy with UDCA and fenofibrate.…”

Section: Current Treatments In Pbc and Pscmentioning

confidence: 99%

Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies—A Critical Overview

Kasztelan-Szczerbińska

Rycyk-Bojarzynska

Szczerbinska

et al. 2023

Nutrients

View full text Add to dashboard Cite

Primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) are rare immune-related cholangiopathies with still poorly explained pathogenesis. Although triggers of chronic inflammation with subsequent fibrosis that affect cholangiocytes leading to obliteration of bile ducts and conversion to liver cirrhosis are unclear, both disorders are regarded to be multifactorial. Different factors can contribute to the development of hepatocellular injury in the course of progressive cholestasis, including (1) body accumulation of bile acids and their toxicity, (2) decreased food intake and nutrient absorption, (3) gut microbiota transformation, and (4) reorganized host metabolism. Growing evidence suggests that intestinal microbiome composition not only can be altered by liver dysfunction, but in turn, it actively impacts hepatic conditions. In this review, we highlight the role of key factors such as the gut–liver axis, intestinal barrier integrity, bile acid synthesis and circulation, and microbiome composition, which seem to be strongly related to PBC and PSC outcome. Emerging treatments and future therapeutic strategies are also presented.

show abstract

Section: Current Treatments In Pbc and Pscmentioning

confidence: 99%